アレルギー性気管支肺アスペルギルス症（ABPA）患者におけるデュピルマブ治療の検討（LIBERTY ABPA AIRED）

基本情報

NCT ID

NCT04442269

ステータス

完了

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

62

治験依頼者名

Regeneron Pharmaceuticals

概要

The primary objective of the study is to evaluate the efficacy of dupilumab on lung function in participants with Allergic Bronchopulmonary Aspergillosis (ABPA). The secondary objectives of the study are: * To evaluate the effects of dupilumab on exacerbations in participants with ABPA * To evaluate the effects of dupilumab on ABPA-related exacerbations * To evaluate the effects of dupilumab on hospitalization/emergency department (ED)/urgent care visits in participants with ABPA * To evaluate the effects of dupilumab on asthma control in participants with ABPA * To evaluate the effects of dupilumab on health-related quality of life (HRQoL) in participants with ABPA * To evaluate the effects of dupilumab on serum total immunoglobulin E (IgE) and Aspergillus-specific IgE concentrations * To evaluate the effects of dupilumab on Fractional exhaled Nitric Oxide (FeNO) levels * To evaluate safety and tolerability of dupilumab in participants with ABPA * To evaluate dupilumab concentrations in serum and the incidence of anti-dupilumab antibodies in participants with ABPA

対象疾患

介入

依頼者（Sponsor）

実施施設 (7)